Trial Status - Open to Recruitment
This is a multi-centre, open label, 2 stage trial in patients with oesophageal cancer
This study will test the combination of a novel ATR inhibitor with radiotherapy or chemoradiotherapy in oesophageal cancer. The design is a phase I, open-label, multicentre, 3-stage, schedule-finding trial using TiTE-CRM (Time-to-Event Continual Reassessment Method).
The narrative publication can be found here.